Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 09, 2023 at 06:12 am EST
Share
Pfizer Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 6,217.5 million compared to INR 6,759 million a year ago. Revenue was INR 6,491.6 million compared to INR 6,941.6 million a year ago. Net income was INR 1,506.6 million compared to INR 1,439.1 million a year ago. Basic earnings per share from continuing operations was INR 32.93 compared to INR 31.46 a year ago.
For the nine months, sales was INR 18,521.2 million compared to INR 20,613.3 million a year ago. Revenue was INR 19,217.9 million compared to INR 21,068.6 million a year ago. Net income was INR 4,942.8 million compared to INR 4,867.7 million a year ago. Basic earnings per share from continuing operations was INR 98.47 compared to INR 106.4 a year ago.
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
PFIZER LIMITED 
